Individual reimbursement of medicines for children with cancer: report shows no unequal treatment
9. September 2022 – The report of the Federal Council establishes that there is no unequal treatment in the approval of cost credits of cancer medication for children by the health insurers. Therefore, there is no action required to improve the individual reimbursement of medicines specifically regarding children with cancer.
For more information, see here.